Behçet's patients' response to COVID-19 vaccination

Area of Science:

• Immunology
• Rheumatology
• Vaccinology

Background:

• SARS-CoV-2 infection can cause multi-system inflammation resembling Behçet's Disease (BD).
• Immunosuppressive therapy for BD raises concerns about COVID-19 vaccine efficacy and safety in patients.
• Evaluating vaccine response in BD patients is crucial due to potential disease flares and altered immunity.

Purpose of the Study:

• To assess COVID-19 vaccine immune response in Behçet's Disease patients compared to healthy controls.
• To investigate factors influencing vaccine response, including age, gender, disease activity, BD phenotype, and immunosuppressive medication.
• To evaluate the impact of COVID-19 vaccination on immune cells, immunoglobulins, thrombophilia, and thyroid function in BD patients.

Main Methods:

• Comparative study measuring anti-spike IgG levels in BD patients and healthy controls post-vaccination.
• Analysis of immune parameters: T and B cells, immunoglobulins, thrombophilia markers, and thyroid function.
• Stratification of BD patient responses based on age, gender, disease activity, BD phenotype, and medication.

Main Results:

• Patients with Behçet's Disease on immunosuppressive medication exhibited a diminished immune response to COVID-19 vaccines.
• Individuals over 40 years old and those with the neurologic BD phenotype showed lower vaccine responses.
• mRNA COVID-19 vaccines demonstrated superior effectiveness and a better side-effect profile compared to conventional vaccines.

Conclusions:

• Immunosuppressive therapy in Behçet's Disease patients significantly impacts COVID-19 vaccine immunogenicity.
• Age and specific BD phenotypes (neurologic) are associated with reduced vaccine effectiveness.
• mRNA COVID-19 vaccines are recommended for Behçet's Disease patients due to enhanced efficacy and tolerability.